| Literature DB >> 23202739 |
Claudia Bagni1, Flora Tassone, Giovanni Neri, Randi Hagerman.
Abstract
Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23202739 PMCID: PMC3533539 DOI: 10.1172/JCI63141
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808